Search results
Results from the WOW.Com Content Network
An estimated 40% of these individuals will have a confirmed cancer diagnosis after a diagnostic evaluation by a health care provider. ... At $949 a pop, it’s out of the price range of most ...
Ratings are updated yearly, but data is two years old before Medicare releases it. [1] [18] [19] Healthgrades develops objective ratings based on data and information from several publicly available sources. [18] The data is analyzed using a proprietary methodology that identifies the recipients of the various awards and the "1-3-5 Star ...
Molecular diagnostics tool can be used for cancer risk assessment. For example, the BRCA1/2 test by Myriad Genetics assesses women for lifetime risk of breast cancer. [22] Also, some cancers are not always employed with clear symptoms. It is useful to analyze people when they do not show obvious symptoms and thus can detect cancer at early stages.
All cancer screening tests generate both false-positive and false-negative results, with a tendency to yield more false positives. [10] False-negative tests may provide a false sense of reassurance, possibly leading to a bad prognosis if the cancer is diagnosed at a later stage, despite the utilization of surgeries, therapies, and other treatments.
Cancer and Metastasis Reviews is a quarterly peer-reviewed medical review journal covering oncology and the development of new cancer treatments. It was established in 1982 and is published by Springer Science+Business Media .
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
In 2015, Becker's Hospital Review recognizes Moffitt's president and CEO Dr. Alan List in its "100 Physician Leaders of Hospitals and Health Systems." [50] Moffitt Cancer Center was named 2017 Nonprofit of the Year by the Tampa Bay Business Journal. Moffitt was also recognized as the category winner in the Health & Human Services category. [51]
The Annual Review of Cancer Biology was first published in 2017, making it the 47th journal title published by Annual Reviews. [5] The stated goals of the journal were to cover the biology of tumor cells, the interaction between the tumor cells and host cells, cancer genomes, drugs for treating cancer, and the resistance of cancer to certain drugs. [6]